PMID: 6540390Aug 1, 1984Paper

Altered pharmacokinetics of L-dopa metabolism in rat striatum deprived of dopaminergic innervation

Neurology
S E Spencer, G F Wooten

Abstract

Rats with unilateral lesions of the substantia nigra were treated with L-dopa 25 mg/kg subcutaneously 30 minutes after treatment with carbidopa 25 mg/kg intraperitoneally. In the ipsilateral striatum, dopamine levels achieved a peak of 1.57 +/- 0.63 micrograms/g (control 0.19 +/- 0.05 micrograms/g) at 20 minutes and did not differ from controls by 90 minutes after L-dopa administration. Dopamine levels peaked in the contralateral striatum at 45 minutes (11.96 +/- 0.14 micrograms/g, where control levels were 7.74 +/- 0.22 micrograms/g) and returned to control values by 180 minutes. These data suggest that in patients with advanced Parkinson's disease, L-dopa administration results in a smaller increase and a shorter duration of elevation in striatal dopamine concentration than in controls. These observations support the hypothesis that the "wearing-off" phenomenon that occurs during the treatment of patients with Parkinson's disease occurs as a consequence of a reduction in the rate of conversion of L-dopa to dopamine and perhaps diminished capacity for the storage of dopamine.

Citations

Jan 1, 1990·Journal of Neural Transmission. Parkinson's Disease and Dementia Section·T BrannanM Yahr
Jan 1, 1987·Pharmacology & Therapeutics·A E Lang
Sep 1, 1995·Progress in Neuro-psychopharmacology & Biological Psychiatry·J M Trugman
Sep 5, 1998·Brain Research. Brain Research Reviews·G L Willis, S M Armstrong
Jan 1, 1993·Journal of Neurology, Neurosurgery, and Psychiatry·R DursoR G Feldman
Oct 17, 2008·Current Medical Research and Opinion·M JogR Schecter
Jan 15, 2016·Journal of Neuroscience Research·Anna-Maija PenttinenMikko Airavaara
Oct 1, 1988·Mayo Clinic Proceedings·J E Ahlskog, M D Muenter
Oct 9, 2007·Parkinsonism & Related Disorders·Peter RiedererHeinz Reichmann
Jul 23, 2005·Movement Disorders : Official Journal of the Movement Disorder Society·Katherine A GrossetDonald G Grosset
Aug 11, 2005·Movement Disorders : Official Journal of the Movement Disorder Society·Katherine A GrossetDonald G Grosset
Feb 1, 1987·Journal of Neurochemistry·P CummingE G McGeer
Oct 1, 1987·Annals of Neurology·M M MouradianT N Chase
Nov 1, 1988·Annals of Neurology·J A ObesoJ M Martínez Lage
Jan 1, 1986·Movement Disorders : Official Journal of the Movement Disorder Society·A E LangC Kierans
Aug 21, 2013·The International Journal of Neuroscience·H Z HashimA M Tamil
Apr 1, 1997·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·P BenetelloM Baraldo
Sep 24, 2008·Handbook of Clinical Neurology·Richard B Mailman, Xuemei Huang
Aug 24, 1999·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·J P LarsenJ E Erdal
Aug 1, 1987·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·A N LiebermanA Neophytides
Nov 17, 1994·Annals of the New York Academy of Sciences·D A LoefflerP A Lewitt
Aug 19, 1999·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·D B King

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.